JOHNSON JOHN

SEC source: 0001867096-22-000090 · wf-form4_165480920373949.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 493,312

F1 · shares: These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.

SEC source: 0000805928-22-000067 · wf-form4_165428722800361.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,459

Underlying: Common Stock · 6,459 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

F1 · derivative.expiration_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0000805928-22-000067 · wf-form4_165428722800361.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,811

Underlying: Common Stock · 11,811 shares

Expires 2032-06-01

F1 · derivative.exercise_date: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year anniversary of the grant date. One-half of the annual equity grant value is in the form of non-qualified stock options and one-half of the annual equity grant value is in the form of restricted stock units.

SEC source: 0001104659-22-128631 · tm2232937-4_4aseq1.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,500

Underlying: Common Stock · 62,500 shares

Expires 2032-05-12

F1 · security: On June 24, 2022 the Reporting Person filed a Form 4 reporting a stock option grant which incorrectly stated an exercise price of $1.11, a transaction date of June 22, 2022 and an expiration date of June 22, 2032. This amendment is being filed to reflect the corrected exercise price of $1.07, transaction date of May 12, 2022 and expiration date of May 12, 2032.

F2 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2022 to May, 2023, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 7

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,600

Underlying: Common Stock · 68,600 shares

Expires 2030-04-08

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 6

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,600

Underlying: Common Stock · 215,600 shares

Expires 2029-11-14

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 5

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2028-05-15

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 4

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2027-05-11

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 3

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2026-05-12

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,367

Underlying: Common Stock · 10,367 shares

Expires 2025-10-16

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039341 · doc4.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,312

F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.

F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.

SEC source: 0001179110-21-009282 · edgar.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 495,724 shares

Expires not disclosed

F2 · derivative.exercise_price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · price: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · derivative.exercise_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

F2 · derivative.expiration_date: Under the Agreement, each option to purchase ordinary shares of Issuer was automatically converted into an option to acquire a number of shares of HoldCo common stock determined by multiplying the number of ordinary shares of Issuer subject to such option by 0.784 (rounded down to the nearest whole share), at an exercise price per share (rounded up to the nearest whole cent) determined by dividing the per-share exercise price of Issuer option by 0.784, with the same terms and conditions as applied to the applicable option prior to closing of the transaction. HoldCo issued one CVR with respect to each ordinary share of Issuer subject to each option prior to the adjustment described herein, subject to the same vesting and forfeiture conditions applicable to the corresponding option.

SEC source: 0001179110-21-009282 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

F1 · price: Ordinary shares of Issuer were converted into shares of common stock of Xeris Biopharma Holdings, Inc. ("HoldCo") pursuant to the Transaction Agreement (the "Agreement"), dated May 24, 2021, among the Issuer, Xeris Pharmaceuticals, Inc., HoldCo and Wells MergerSub, Inc. Under the Agreement, each ordinary share of Issuer was exchanged for 0.784 of a share of HoldCo common stock, and cash in lieu of fractional shares, plus one contingent value right (a "CVR") worth up to an additional $1.00, payable in cash, HoldCo common stock or a combination thereof at HoldCo's sole election.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 8

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,650

Underlying: Common Stock · 19,650 shares

Expires 2031-10-05

F4 · derivative.exercise_date: One third of these options shall vest in equal annual installments until the third anniversary of the date of grant.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 7

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,600

Underlying: Common Stock · 68,600 shares

Expires 2030-04-08

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 6

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,600

Underlying: Common Stock · 215,600 shares

Expires 2029-11-14

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 5

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2028-05-15

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 4

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2027-05-11

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 3

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,360

Underlying: Common Stock · 31,360 shares

Expires 2026-05-12

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,367

Underlying: Common Stock · 10,367 shares

Expires 2025-10-16

F2 · kind: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F2 · price: At the Merger Effective Time, each option to purchase ordinary shares of Strongbridge (the "Strongbridge Option") that was outstanding immediately prior to the Merger Effective Time, whether vested or unvested, was automatically converted into an option to purchase shares of HoldCo common stock (the "HoldCo Option") on a 0.7840-for-one basis, on the same terms and conditions (including any applicable vesting and exercisability requirements) as were applicable to such Strongbridge Option immediately prior to the Merger Effective Time.

F3 · derivative.exercise_date: These options are fully vested as of the date hereof.

SEC source: 0000899243-21-039749 · doc4a.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,312

F1 · kind: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.

F1 · price: On October 5, 2021, pursuant to the transaction agreement dated as of May 24, 2021 ("Transaction Agreement") by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge (the "Acquisition"), and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger", and together with the Acquisition, the "Transaction"). At the effective time of the Merger (the "Merger Effective Time"), all existing ordinary shares of Strongbridge were cancelled and automatically converted into the right to receive HoldCo common stock on a 0.7840-for-one basis.

SEC source: 0001179110-21-009224 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,092

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0000899243-21-029207 · doc4.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,638

Underlying: Common Stock · 27,638 shares

Expires 2031-07-19

F1 · derivative.exercise_date: The shares subject to this option will vest in three equal installments on the annual anniversary of the grant date with the first vesting date occurring on July 19, 2022.

SEC source: 0001179110-21-007439 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 944,960

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001104659-21-087403 · tm2121071-5_4seq1.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-06-28

F1 · derivative.exercise_date: The stock option vests in twelve equal month installments (rounded down to the nearest whole share on each vesting date except with respect to the final vesting date on which the remaining unvested portion shall vest) beginning on the on the last day of each month over a period from June, 2021 to May, 2022, provided that the Reporting Person continues to serve as a director of the Company on each such vesting date.

SEC source: 0001179110-21-004361 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 995,827

F1 · shares: Shares withheld by the Issuer to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001179110-21-000424 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,013,152

F1 · shares: Represents a grant of restricted stock units, which vest in full on January 7, 2023, provided the Reporting Person is employed by the Issuer on such date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001209191-20-040321 · doc4.xml · derivative · entry 4

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 54,991 shares

Expires not disclosed

F4 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment.

F4 · price: In connection with the Merger, these options were accelerated and canceled without payment.

F4 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment.

F4 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment.

SEC source: 0001209191-20-040321 · doc4.xml · derivative · entry 3

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,377 shares

Expires 2030-06-11

F3 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F3 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

SEC source: 0001209191-20-040321 · doc4.xml · nonDerivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · acquired: At the Effective Time, each restricted stock unit ("RSU") was accelerated and canceled as of immediately prior to, and contingent upon, the Effective Time, in exchange for the right to receive a cash amount equal to the product of (i) the number of shares deliverable under such RSU multiplied by (ii) $18.00.

SEC source: 0001209191-20-040321 · doc4.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

SEC source: 0001179110-20-008088 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 522,152

F1 · shares: Represents a grant of restricted stock units ("RSUs"). One-half of the RSUs will vest on July 2, 2021 with the remaining one-half of the RSUs vesting on July 2, 2022, provided the Reporting Person is employed by, or providing services to, the Issuer on each vesting date. Each RSU represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0000904454-20-000404 · edgar.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,602

Underlying: Common Stock · 27,602 shares

Expires 2030-06-16

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on June 30, 2020 and ending on May 31, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

SEC source: 0001209191-20-036767 · doc4.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,377

Underlying: Common Stock · 11,377 shares

Expires 2030-06-11

F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-20-036767 · doc4.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,475

F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2021, subject to the Reporting Person's Continuous Services (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date.

SEC source: 0001179110-20-006239 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 207,152

F1 · shares: Shares withheld by Strongbridge Biopharma plc to satisfy taxes payable in connection with the vesting of previously awarded restricted stock units.

SEC source: 0001104659-20-053602 · a4.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2030-04-29

F1 · derivative.exercise_date: The option vests in twelve equal monthly installments (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which the remaining unvested portion shall vest), beginning on May 29, 2020 and ending on April 29, 2021, provided that the Reporting Person continues to serve as a director of the Issuer on each such vesting date.

SEC source: 0001179110-20-004824 · edgar.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,500

Underlying: Common Stock · 87,500 shares

Expires 2030-04-08

F2 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning May 8, 2020, provided that the Reporting Person continues to serve as Executive Chairman and as a member of the board of directors of the Issuer through each such vesting date.

SEC source: 0001179110-20-004824 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 222,500

F1 · shares: Represents a grant of restricted stock units, which vest in three equal annual installments on each of the first three anniversaries of the grant date, provided that the Reporting Person continues to serve as Executive Chairman and as a member of the board of directors of the Issuer through each such vesting date. Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.

SEC source: 0001179110-19-011796 · edgar.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2029-11-14

F1 · shares: Granted in connection with the Reporting Person's appointment as executive chairman of the Issuer.

F2 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning February 14, 2020, provided the Reporting Person is employed by or serving as a director of the Issuer on each vesting date.

SEC source: 0001461993-19-000037 · wf-form4_156211615828793.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,400

F1 · shares: Represents the number of shares necessary to cover tax withholding obligations in connection with the vesting of the Reporting Person's RSUs.

SEC source: 0001209191-19-037457 · doc4.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,991

Underlying: Common Stock · 6,991 shares

Expires 2029-06-12

F2 · derivative.exercise_date: The Option shall vest as follows: 1/12th of the shares subject to the option shall vest on the first of each month after the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-19-037457 · doc4.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,194

F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs fully vest on March 1, 2020, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2013 Equity Incentive Plan) as of such date.

SEC source: 0001461993-19-000035 · wf-form4_156157960106867.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Melinta Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date.

F1 · derivative.expiration_date: The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date.

SEC source: 0001461993-19-000035 · wf-form4_156157960106867.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,400

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-19-006149 · edgar.xml · nonDerivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · shares: Represents a grant of restricted stock units, which vest in full on May 15, 2020, provided that the Reporting Person continues to serve as a member of the board of directors of the Issuer through that date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

SEC source: 0000899243-19-004939 · doc4.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires not disclosed

F1 · derivative.exercise_date: The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date.

F1 · derivative.expiration_date: The restricted stock units will vest in equal quarterly installments over the two year period following February 22, 2019, subject to Mr. Johnson's continued service with the Issuer through the applicable vesting date.

SEC source: 0000899243-18-027585 · doc4.xml · derivative · entry 2

JOHNSON JOHN · CIK 0001410781 · Director · Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · derivative.exercise_date: The award vests in full and will be settled on October 18, 2019, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors).

F2 · derivative.expiration_date: The award vests in full and will be settled on October 18, 2019, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors).

SEC source: 0000899243-18-027585 · doc4.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director · Interim CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-10-26

F1 · derivative.exercise_date: The award vests in equal monthly installments over a period of 12 months from October 18, 2018, subject to the Reporting Person continuing to provide services in any capacity (including, but not limited to, service as a member of the Board of Directors).

SEC source: 0000899243-18-017186 · doc4.xml · derivative · entry 1

JOHNSON JOHN · CIK 0001410781 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2028-06-14

F1 · derivative.exercise_date: This option vests and becomes exercisable with respect to 8.33% of the option shares for each one-month period following June 15, 2018.